Endonuclease-mediated disruption of latent HSV as curative therapy
核酸内切酶介导的潜伏 HSV 破坏作为治疗方法
基本信息
- 批准号:10593355
- 负责人:
- 金额:$ 15.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-06-12 至 2023-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Project Summary
Herpes simplex virus (HSV) infections remain a common, serious problem associated with significant
morbidity. After primary infection, HSV establishes latency, which is not eliminated by current antiviral therapy.
Latent virus is the source for viral reactivation and the recurrence of clinical disease. Despite much effort, a
vaccine remains elusive. Therefore, there is a need for a novel therapeutic approach that would cure
latent HSV infection. We have been developing a new curative strategy to latent HSV infection, in which an
HSV-targeted endonuclease induces mutagenesis of essential HSV genes, disabling viral genomes and
rendering the virus incapable of replication or reactivation from latency. Our hypothesis is that recent advances
in the field of gene-editing technologies and in vivo gene delivery offer the opportunity to improve our current
anti-viral approach and reach therapeutic efficacy. Here, we propose to evaluate Staphylococcus aureus
(Sa)CRIPSR/Cas9 and homing endonucleases (HEs) for their ability to disable HSV in latently infected
neurons by targeted viral genome disruption, thus eliminating the source of viral pathogenesis in an animal
model of HSV infection. The goal of this project is to maximize the efficacy and safety of our approach to
eliminate latent HSV infection in vivo, using a murine model of HSV latent infection. Our results will also be
applicable in efforts to cure varicella zoster virus, another alphaherpesvirus that like HSV establishes latency in
sensory neurons. Furthermore, the data generated will be highly relevant to the development of cures for other
chronic or latent viral infections such as hepatitis B virus, HIV, or human papillomavirus.
In SA1: Address the remaining barriers to effective in vivo HSV gene editing, we will compare 1) new
AAV serotypes to our current AAV serotypes for transgene delivery after administration via different routes,
and 2) the gene editing abilities of CRISPR/Cas9 vs. HEs. In SA2: Optimize the efficacy of in vivo gene
editing and determine the impact on viral pathogenesis, we will evaluate whether the simultaneous
targeting of two HSV sites provides superior efficacy over targeting a single site, and the efficacy of gene
editing necessary to impact viral pathogenesis. In SA3: Evaluate the safety of in vivo gene editing in our
mouse model, we will use our mouse model of latent HSV infection to evaluate tolerability, safety, and
genotoxicity of nuclease exposure.
This project is expected to demonstrate the feasibility of our therapeutic approach directed towards the
elimination of HSV pathogenesis in vivo, and to provide critical information for the development of a larger
scale animal study necessary to bring this new therapeutic approach to the clinic.
项目摘要
单纯疱疹病毒(HSV)感染仍然是一种常见的、严重的问题,与严重的
发病率初次感染后,HSV建立潜伏期,目前的抗病毒治疗无法消除。
潜伏病毒是病毒再激活和临床疾病复发的根源。尽管付出了很多努力,A
疫苗仍然难以捉摸。因此,需要一种新的治疗方法,
潜伏性HSV感染。我们一直在开发一种新的治疗策略来治疗潜伏性HSV感染,
HSV-靶向核酸内切酶诱导必需HSV基因的诱变,使病毒基因组失能,
使病毒不能复制或从潜伏期重新激活。我们的假设是最近的进展
在基因编辑技术和体内基因递送领域,
抗病毒方法并达到治疗效果。在这里,我们建议评估金黄色葡萄球菌
(Sa)CRIPSR/Cas9和归巢核酸内切酶(HE)在潜伏感染的HSV中使HSV失能的能力,
通过靶向病毒基因组破坏神经元,从而消除动物中病毒发病的来源
HSV感染模型。该项目的目标是最大限度地提高我们的方法的有效性和安全性,
使用HSV潜伏感染的鼠模型消除体内潜伏HSV感染。我们的结果也将是
可用于治疗水痘带状疱疹病毒,另一种α疱疹病毒,如HSV建立潜伏期,
感觉神经元此外,所产生的数据将与其他疾病的治疗方法的发展高度相关。
慢性或潜伏性病毒感染,如B型肝炎病毒、HIV或人乳头瘤病毒。
在SA 1中:解决有效体内HSV基因编辑的剩余障碍,我们将比较1)新的
AAV血清型与我们目前的AAV血清型在通过不同途径施用后用于转基因递送,
和2)CRISPR/Cas9相对于HE的基因编辑能力。在SA 2中:优化体内基因的功效
编辑和确定对病毒发病机制的影响,我们将评估是否同时
两个HSV位点的靶向提供了优于靶向单个位点的上级功效,并且基因治疗的功效与靶向单个位点的功效相同。
编辑影响病毒发病机制所必需的。在SA 3中:评估我们的体内基因编辑的安全性
小鼠模型,我们将使用我们的潜伏性HSV感染的小鼠模型来评估耐受性、安全性和
核酸酶暴露的遗传毒性。
该项目有望证明我们的治疗方法的可行性,
消除体内HSV发病机制,并为开发更大的
将这种新的治疗方法引入临床所需的大规模动物研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KEITH R JEROME其他文献
KEITH R JEROME的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KEITH R JEROME', 18)}}的其他基金
Endonuclease-mediated disruption of latent HSV as curative therapy
核酸内切酶介导的潜伏 HSV 破坏作为治疗方法
- 批准号:
10155424 - 财政年份:2018
- 资助金额:
$ 15.5万 - 项目类别:
Endonuclease-mediated disruption of latent HSV as curative therapy
核酸内切酶介导的潜伏 HSV 破坏作为治疗方法
- 批准号:
10182099 - 财政年份:2018
- 资助金额:
$ 15.5万 - 项目类别:
Endonuclease-mediated disruption of latent HSV as curative therapy
核酸内切酶介导的潜伏 HSV 破坏作为治疗方法
- 批准号:
9597105 - 财政年份:2018
- 资助金额:
$ 15.5万 - 项目类别:
Endonuclease-mediated disruption of latent HSV as curative therapy
核酸内切酶介导的潜伏 HSV 破坏作为治疗方法
- 批准号:
10405036 - 财政年份:2018
- 资助金额:
$ 15.5万 - 项目类别:
Endonuclease-mediated disruption of latent HSV as curative therapy
核酸内切酶介导的潜伏 HSV 破坏作为治疗方法
- 批准号:
9927580 - 财政年份:2018
- 资助金额:
$ 15.5万 - 项目类别:
In vivo inactivation of latent HSV by endonuclease-mediated mutagenesis
通过核酸内切酶介导的诱变体内潜伏 HSV 灭活
- 批准号:
9199202 - 财政年份:2016
- 资助金额:
$ 15.5万 - 项目类别:
In vivo inactivation of latent HSV by endonuclease-mediated mutagenesis
通过核酸内切酶介导的诱变体内潜伏 HSV 灭活
- 批准号:
9035463 - 财政年份:2016
- 资助金额:
$ 15.5万 - 项目类别:
Targeted Modification of Host and Proviral DNA to Treat Latent HIV Infection
宿主和原病毒 DNA 的靶向修饰治疗潜伏性 HIV 感染
- 批准号:
8691703 - 财政年份:2011
- 资助金额:
$ 15.5万 - 项目类别:
相似国自然基金
PfAP2-R介导的PfCRT转录调控在恶性疟原虫对喹啉类药物抗性中的作用及机制研究
- 批准号:82372275
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
基于NLRP3/IL-1β信号探讨α7nAChR介导巨噬细胞—心肌细胞互作在Aβ诱导房颤心房重构中的作用及机制研究
- 批准号:82300356
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
Tom1L1在胞内体蛋白分选机制中功能的研究
- 批准号:31171289
- 批准年份:2011
- 资助金额:56.0 万元
- 项目类别:面上项目
溶酶体依赖性TRAF2降解的机制
- 批准号:30971501
- 批准年份:2009
- 资助金额:31.0 万元
- 项目类别:面上项目
相似海外基金
DEFINING MECHANISMS UNDERPINNING ANTIBIOTIC MEDIATED DISRUPTION OF PULMONARY IMMUNE RESPONSES
定义抗生素介导的肺免疫反应破坏的机制
- 批准号:
MR/Y008812/1 - 财政年份:2024
- 资助金额:
$ 15.5万 - 项目类别:
Research Grant
Oral pathogen - mediated pro-tumorigenic transformation through disruption of an Adherens Junction - associated RNAi machinery
通过破坏粘附连接相关的 RNAi 机制,口腔病原体介导促肿瘤转化
- 批准号:
10752248 - 财政年份:2024
- 资助金额:
$ 15.5万 - 项目类别:
Mrgprb2 mediated neuroinflammation after cerebral ischemia
Mrgprb2介导脑缺血后的神经炎症
- 批准号:
10644182 - 财政年份:2023
- 资助金额:
$ 15.5万 - 项目类别:
Investigating the role and therapeutic potential of the alpha5beta1 integrin in risk factors for COVID-19-associated cognitive impairment
研究 α5β1 整合素在 COVID-19 相关认知障碍危险因素中的作用和治疗潜力
- 批准号:
10658178 - 财政年份:2023
- 资助金额:
$ 15.5万 - 项目类别:
Elucidation of ALS pathology caused by disruption of NEK1-mediated cell signaling pathway
阐明 NEK1 介导的细胞信号通路破坏引起的 ALS 病理学
- 批准号:
22K15702 - 财政年份:2022
- 资助金额:
$ 15.5万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Examining HIV-mediated disruption of CNS immune homeostasis using a triple humanized mouse
使用三重人源化小鼠检查 HIV 介导的中枢神经系统免疫稳态破坏
- 批准号:
10705753 - 财政年份:2022
- 资助金额:
$ 15.5万 - 项目类别:
Improved delivery of gene therapies to the central nervous system by focused ultrasound-mediated disruption of the blood-brain barrier
通过聚焦超声介导的血脑屏障破坏,改善中枢神经系统基因治疗的传递
- 批准号:
10443357 - 财政年份:2022
- 资助金额:
$ 15.5万 - 项目类别:
Cytokine-mediated neurologic disease in COVID-19
COVID-19 中细胞因子介导的神经系统疾病
- 批准号:
10509125 - 财政年份:2022
- 资助金额:
$ 15.5万 - 项目类别:
Mechanisms of Salmonella-mediated disruption of colonization resistance in the inflamed gut
沙门氏菌介导的炎症肠道定植抵抗破坏机制
- 批准号:
10595200 - 财政年份:2022
- 资助金额:
$ 15.5万 - 项目类别:
Examining HIV-mediated disruption of CNS immune homeostasis using a triple humanized mouse
使用三重人源化小鼠检查 HIV 介导的中枢神经系统免疫稳态破坏
- 批准号:
10536487 - 财政年份:2022
- 资助金额:
$ 15.5万 - 项目类别: